Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
HOUSTON , May 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the
View HTML
Toggle Summary Aravive Announces Retrospective Analysis Showing Increased GAS6 Levels Associated with Chemoresistance and Decreased Progression Free Survival in Ovarian Cancer
Data from Non-clinical Ovarian Cancer Study of AVB-500 and Proprietary GAS6 Biomarker Presented at the Society of Gynecologic Oncology’s 50th Annual Meeting HOUSTON , March 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that data
View HTML
Toggle Summary Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference
HOUSTON , March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: Event: Cowen and Company 39th Annual Health Care Conference Presentation Date &
View HTML
Toggle Summary Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates
HOUSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company focused on developing innovative therapies that target important survival pathways for cancer, announced recent corporate updates and financial results for the fourth quarter and
View HTML
Toggle Summary Aravive to Report Fourth Quarter and Full Year 2018 Financial Results and Corporate Updates on March 7, 2019
HOUSTON , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced the company plans to report financial results for the fourth quarter and full year 2018 and provide corporate updates on March 7, 2019 after the close of the U.S.
View HTML
Toggle Summary Aravive Receives Additional $2.6 Million Disbursement from the Cancer Prevention and Research Institute of Texas
HOUSTON , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has received an additional $2.6 million disbursement from the Cancer Prevention and Research Institute of Texas (CPRIT).
View HTML
Toggle Summary Aravive Expands Executive Team with Promotion of Gail McIntyre, PhD, DABT to Chief Scientific Officer
HOUSTON , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the company has promoted Gail McIntyre , PhD, DABT to chief scientific officer. “Aravive continues to work towards its goal of bringing innovative therapies to
View HTML
Toggle Summary Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019
HOUSTON , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on the GAS6-AXL pathway and its role in cancer, as well as the clinical development landscape of
View HTML
Toggle Summary Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer
HOUSTON , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients
View HTML
Toggle Summary Aravive Announces Participation at Upcoming Investor Conference
HOUSTON , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference: Event: Piper Jaffray Healthcare Conference Presentation Date & Time: Tuesday,
View HTML